8-KEarnings & ResultsExhibits & Filings

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Financial Results (Jan 27, 2016)

Filed January 27, 2016For Securities:VRTX

Summary

Vertex Pharmaceuticals Inc. (VRTX) filed an 8-K on January 27, 2016, to report its consolidated financial results for the fourth quarter and full fiscal year ended December 31, 2015. The press release containing these results, attached as Exhibit 99.1, serves as the primary disclosure for this filing. Investors should refer to the attached press release for detailed financial performance metrics, including revenue, net income, and earnings per share for the periods ended December 31, 2015. While the 8-K itself is brief, its purpose is to formally incorporate the press release's financial information. This filing indicates that Vertex is providing its latest financial performance update to the market. For a comprehensive understanding of Vertex's financial health and operational results for the year 2015, a thorough review of the press release is essential. It is important to note the cautionary statement regarding the information in the press release not being deemed "filed" under certain sections of the Securities Exchange Act, although it is incorporated by reference.

Key Highlights

  • 1Vertex Pharmaceuticals (VRTX) reported its financial results for the fourth quarter and full year ended December 31, 2015, via an 8-K filing on January 27, 2016.
  • 2The key financial information is contained within a press release furnished as Exhibit 99.1 to the 8-K.
  • 3Investors are directed to the attached press release for specific details on the company's financial performance.
  • 4The filing covers results for both the three months and the twelve months ended December 31, 2015.
  • 5The press release information is incorporated by reference into the 8-K filing.
  • 6A standard disclaimer is included, stating the press release information is not deemed 'filed' for purposes of Section 18 of the Exchange Act.

Frequently Asked Questions

The main purpose of this 8-K filing is to formally report Vertex Pharmaceuticals' consolidated financial results for the fourth quarter and the full fiscal year ended December 31, 2015, by attaching the relevant press release.

The detailed financial results are presented in the press release dated January 27, 2016, which is attached as Exhibit 99.1 to this 8-K filing and incorporated by reference.

Based on the provided content, this 8-K filing specifically focuses on reporting financial results for the periods ended December 31, 2015. Any operational or strategic updates would need to be reviewed within the attached press release itself.

The disclaimer means that while the information is being disclosed through the 8-K, it is not subject to the same liability provisions under Section 18 of the Securities Exchange Act of 1934 as if it were formally 'filed' in other contexts. However, it is still considered important information for investors.